A study of changes in the bone mineral density associated with the use of different vitamin D3 preparations concomitantly with denosumab treatment
2025 Volume 50 Issue 1 Pages 1-5
Details
2025 Volume 50 Issue 1 Pages 1-5
Objective: In this study, we investigated the changes in the bone mineral density (BMD) associated with concomitant use of different vitamin D3 (Vit D3) preparations in women with osteoporosis receiving denosumab (DMAB) treatment.
Methods: A total of 146 women with osteoporosis who were receiving treatment with DMAB between April 2015 and July 2023 were divided into an active D3 group (eldecalcitol, Group E, n = 55) and a native D3 group (DENOTAS®, Group D, n = 91), and the changes in the BMD in the lumbar vertebrae, femoral neck, and proximal femur following treatment were compared between the two groups.
Results: No significant differences in the BMD between Group D and Group E were observed during follow-up of the patients in any of the lumbar vertebrae (0.764 [± 0.180] g/cm2 vs. 0.748 [± 0.163] g/cm2), femoral neck (0.490 [± 0.081] g/cm2 vs. 0.488 [± 0.072] g/cm2), or proximal femur (0.625 [± 0.097] g/cm2 vs. 0.636 [± 0.094] g/cm2).
Discussion: While the use of active Vit D3 is generally considered as being advantageous for increasing the BMD, we found no differences in the BMD/percent changes in the BMD between the active and native Vit D3 groups in our study.
Conclusion: Our study suggests that either active or native Vit D3 could be used as a supplement to prevent hypocalcemia in osteoporosis patients receiving DMAB treatment.
